Miconazole%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520vaginal%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520pessary

# Miconazole Vaginal Pessary ## Overview Miconazole is an imidazole antifungal agent. The vaginal pessary is formulated for localized vaginal administration to treat vulvovaginal candidiasis. ## Primary Indications Treatment of vulvovaginal candidiasis (yeast infections) caused by susceptible Candida species. ## Adult Dosing * **100 mg pessary:** Insert one pessary vaginally at bedtime for 7 consecutive days. * **200 mg pessary:** Insert one pessary vaginally at bedtime for 3 consecutive days. * **Intravaginal cream (if available as a single-dose applicator):** A single dose of 100 mg or 200 mg can be administered. The duration of therapy depends on the specific product formulation and strength. ## Pediatric Dosing Dosing for pediatric patients has not been established for the vaginal pessary formulation. Use in pediatric patients is generally not recommended unless specifically directed by a healthcare provider. ## Dose Adjustments No dose adjustments are typically required based on renal or hepatic impairment for vaginal administration due to minimal systemic absorption. ## Contraindications * Hypersensitivity to miconazole or any component of the formulation. * Use with CYP3A4 inhibitors (e.g., certain antiretrovirals, macrolides, calcium channel blockers) is generally avoided due to potential for increased systemic miconazole levels and associated toxicities, though systemic absorption from vaginal pessaries is low. ## Adverse Effects * **Common:** Vulvovaginal burning or itching, local irritation, vaginal discharge, abdominal cramping. * **Less Common:** Rash, urticaria, dyspareunia. ## Key Drug Interactions Systemic absorption from vaginal pessaries is minimal, but theoretically, miconazole can inhibit CYP3A4 enzymes. Concurrent use with systemic CYP3A4 substrates (e.g., warfarin, some statins, certain immunosuppressants) may increase systemic drug levels. However, the clinical significance of this interaction with vaginal formulations is likely low. ## Monitoring * Monitor for symptom improvement (e.g., reduction in itching, burning, discharge). * Assess for local adverse effects. ## Clinical Pearls * Complete the full course of therapy as prescribed, even if symptoms improve earlier. * Avoid sexual intercourse during treatment to prevent potential transmission and to ensure efficacy. * Avoid concurrent use of latex condoms or diaphragms, as miconazole can weaken these materials, leading to failure. * If symptoms do not improve after completing the course, or if symptoms worsen, re-evaluate the diagnosis and consider alternative therapy. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols for definitive guidance. Clinical decisions should be based on individual patient assessment.